Not absolutely all anti-hypertensive medications are equal.

However, the trial didn’t show a significant difference between the treatments in either cardiovascular or renal events. ATTEMPT-CVD measured the impact of both telmisartan and non-ARBs on urinary albumin creatinine ratio and plasma brain natriuretic peptide . Patients with hypertension from 168 establishments in Japan were randomised to receive telmisartan or a non-ARB antihypertensive medication and followed for three years. The primary efficacy endpoints were changes from baseline in plasma and UACR BNP amounts. Elevations in either of the biomarkers are believed risk factors for CVD. Secondary endpoints had been changes in other biomarkers, including serum high-sensitivity C-reactive protein levels, urinary 8-hydroxy-deoxy-guanosine , serum adiponectin, approximated glomerular filtration rate , and high-molecular weight adiponectin amounts.The news headlines service writes: Infrastructure advancement is an integral concern being discussed at the meeting. Rapid urbanization has led to 72 % of Africa’s population surviving in slum settlements in cities and towns, Anna Tibaijuka, executive director of the US Human Settlements Program, told reporters in Dar sera Salaam today .This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the complete Kaiser Daily Health Plan Survey, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, discussions and debates. The Kaiser Daily Wellness Policy Report is published for, a free service of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Panel Kaiser and Company Family members Foundation.